Imagine a world where tuberculosis (TB), a disease that silently infects one-quarter of the global population, could be eradicated with a simple breath. Sounds like science fiction, right? But what if an inhaled vaccine could make this a reality? While TB has largely disappeared from the Global North, it remains a devastating killer, claiming 1.5 million lives annually. And this is the part most people miss: the current vaccine, Bacillus Calmette-Guérin (BCG), is surprisingly ineffective against pulmonary TB in adults, the very form that wreaks havoc in high-burden regions.
In a groundbreaking study, Australian researchers have uncovered a potential game-changer. They’ve found that inhaling a modified, more potent version of the BCG vaccine activates specialized cells in the lungs, essentially training the immune system to fight TB locally. This discovery, published in Mucosal Immunology, offers a glitch of hope for a more effective vaccine. But here's where it gets controversial: should we tinker with a vaccine that’s already saved countless lives, even if it means potentially exposing people to a more virulent strain?
Associate Professor Andreas Kupz, a leading researcher at James Cook University, explains the dilemma. “We need a vaccine that works for everyone, not just children,” he says. While BCG protects children from disseminated TB, its effectiveness wanes in adolescence and adulthood, leaving a gaping hole in our defenses. Kupz and his team are exploring three strategies: developing entirely new vaccines (like mRNA or protein-based ones), changing the way the vaccine is delivered, and improving the existing BCG vaccine itself.
Interestingly, early trials of new vaccine types haven’t outperformed BCG, highlighting its enduring strength. Kupz believes enhancing BCG might be the most promising path. “BCG’s complexity, with its 4,000 proteins, makes it a tough act to follow,” he notes. However, making BCG more potent also raises safety concerns, as increased virulence can be risky. The key lies in finding the perfect balance between safety and immune response.
One intriguing finding is that delivering BCG directly into the lungs, rather than under the skin, provides superior protection in animal models. This mucosal delivery method seems to be the secret sauce, but why? Kupz’s team is unraveling the mechanisms behind this, focusing on how the vaccine induces and maintains protective T cells in the lungs over the long term.
Historically, BCG was first administered orally in the 1920s, but this practice was abandoned after a tragic incident in Lübeck. Yet, Kupz points out that the original intent was to mimic the immune response of intravenous delivery, which has shown remarkable protection in primates. While intravenous vaccination isn’t practical for humans, especially newborns, it sheds light on why alternative delivery methods might be more effective.
Human trials are already underway at Oxford University, testing the safety and immunogenicity of inhaled BCG. These trials are crucial for determining the right dose and understanding potential side effects. Meanwhile, the COVID-19 pandemic has brought TB back into the spotlight, revealing both the challenges of diagnosis and treatment during lockdowns and the urgent need for better vaccines.
TB disproportionately affects disadvantaged populations, including First Nations Australians, who face infection rates 5-6 times higher than the general population. The World Health Organization aptly describes TB as a disease of poverty, vulnerability, and stigma. Addressing this disparity isn’t just a scientific challenge—it’s a moral imperative. Kupz emphasizes our responsibility to communities like those in Papua New Guinea (PNG), where multidrug-resistant TB is rampant. The Torres Strait Treaty, allowing free movement between PNG and Australia, further complicates biosecurity efforts, making local solutions even more critical.
Looking ahead, Kupz’s team has developed a modified BCG strain that boosts immunity without increasing virulence, a step closer to a safer vaccine. However, funding remains a significant hurdle. “We know what works better, but we need the resources to make it safe for mass vaccination,” Kupz says. The question now is: will the world prioritize this silent killer, or will TB continue to thrive in the shadows of neglect?
What do you think? Is modifying the BCG vaccine worth the risk, or should we focus on entirely new approaches? Share your thoughts in the comments below.
